Dive into the evolution of GLP-1 use New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more As the demand for glucagon-like peptide-1 (GLP-1) agonist medications for weight loss continues to climb, Prime Therapeutics (Prime) is uniquely positioned to manage this rapidly evolving drug class
Its a handful of smaller onesdigestion, blood sugar, rewardall shifting at the same time
These symptoms are generally mild and may improve over time
Regular physical activity, preferably earlier in the day, can promote better sleep quality and supports weight management goals
There is also more evidence and reports about its possible serious adverse effects, she added
[PMID: 10734331] PubMed record related to this compound for laboratory literature review